Cortexyme Announces Upcoming Data Presentations at November 2020 Conferences
-- Oral presentation at Clinical Trials on Alzheimer's Disease 2020 will include baseline characteristics of the Phase 2/3 GAIN Trial ahead of planned interim analysis expected to occur before year-end 2020 --
-- Poster at Society for Immunotherapy of Cancer Annual Meeting evaluates the therapeutic potential of gingipain inhibitors in oncology --
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Cortexyme Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering potential therapeutics for Alzheimer’s and other degenerative diseases, announced that its work will be the subject of abstracts at two upcoming scientific conferences: the 13th Clinical Trials on Alzheimer's Disease Digital Event (CTAD 2020; November 4-7) and the Society for Immunotherapy of Cancer’s 35th Anniversary Annual Meeting (SITC; November 9-14).
The oral presentation at CTAD 2020 will provide an update on Cortexyme’s ongoing Phase 2/3 GAIN Trial, which is evaluating atuzaginstat in more than 570 patients with mild to moderate Alzheimer’s disease (AD). Atuzaginstat targets the toxic proteases, or gingipains, produced by P. gingivalis, which have been discovered in greater than 90% of post-mortem brains of patients with AD and shown to produce Alzheimer’s disease pathology in infected animals. By targeting these gingipains, Cortexyme hopes to slow or halt the progression of AD. The CTAD abstract, “Phase 2/3 GAIN trial of atuzaginstat (COR388), a novel bacterial virulence factor inhibitor for the treatment of Alzheimer’s disease: Update and baseline data,” will be presented on Thursday, November 5th at 11:02 a.m. EST / 8:02 a.m. PST.
The poster at SITC 2020 demonstrates the potential for atuzaginstat and other gingipain inhibitors to reduce the expression of the immune checkpoint ligand PD-L1 induced by P. gingivalis infection. P. gingivalis has been previously linked to increased risk and worse outcomes in oral, esophageal and other cancers and has been shown to induce PD-L1 on the surface of infected cells, which may allow cancers to evade the immune system. The poster (Abstract #676), “PD-L1 is induced by the periodontal pathogen Porphyromonas gingivalis and can be blocked by small molecule gingipain inhibitors, including atuzaginstat,” will be on display in the meeting’s virtual poster hall from 8:00 a.m. EST / 5:00 a.m. PST on Monday, November 9th.
Both presentations will be available at https://ir.cortexyme.com/news-and-events/presentations.
“As we advance the GAIN Trial of our lead investigational medicine, atuzaginstat, in mild to moderate Alzheimer’s disease, our research team also continues to make strides in understanding the critical role that P. gingivalis may play in a variety of therapeutic areas and the corresponding benefits of atuzaginstat,” said Casey Lynch, Cortexyme’s chief executive officer, co-founder, and chair. “We are looking forward to continuing to expand our understanding of the potential benefits of our small molecule library.”
About Cortexyme, Inc.
Cortexyme, Inc. (Nasdaq: CRTX) is a clinical stage biopharmaceutical company pioneering upstream therapeutic approaches designed to improve the lives of patients diagnosed with Alzheimer’s and other degenerative diseases. Based upon the evidence generated to date, Cortexyme is currently advancing its lead therapeutic candidate, atuzaginstat (COR388), in the GAIN Trial, an ongoing Phase 2/3 clinical trial in patients with mild to moderate Alzheimer’s disease. Cortexyme is targeting a specific, infectious pathogen found in the brain of Alzheimer’s patients and tied to neurodegeneration and neuroinflammation in animal models. To learn more about Cortexyme, visit www.cortexyme.com or follow @Cortexyme on Twitter.
Statements in this press release contain “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “expect,” “believe,” “will,” “may,” “should,” “estimate,” “project,” “outlook,” “forecast” or other similar words. Examples of forward-looking statements include, among others, statements we make regarding our business plans and prospects, the translation to human of pre-clinical data, the pre-clinical results for our product candidates, the timing and success of our clinical trials and related data including the outcome of the interim analysis, the potential of atuzaginstat to treat Alzheimer’s disease and the potential therapeutic application in oncology, our ability to fund planned operating and capital expenditures, the timing of announcements and updates relating to our clinical trials and related data, the timing of and our ability to enroll patients into our clinical trials, and the potential therapeutic benefits, safety and efficacy of our product candidate or library of compounds. Forward-looking statements are based on Cortexyme’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and could cause actual results to differ materially from what we expect. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. Factors that could cause actual results to differ include, but are not limited to, the risks and uncertainties described in the section titled “Risk Factors” in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC) on March 16, 2020, our Quarterly Report on Form 10-Q filed with the SEC on August 14, 2020, and other reports as filed with the SEC. Forward-looking statements contained in this press release are made as of this date, and Cortexyme undertakes no duty to update such information except as required under applicable law.
Source: Cortexyme, Inc.